The VIPS technology was invented at University of California at Berkeley by Drs. Boris Rubinsky and Cesar Gonzalez. VIPS exploits the changes in electrical properties of tissue as a result of small changes in fluids. These changes in electrical properties can be detected by measuring the frequency response of the phase angle between a transmitter and receiver antenna.
There is a critical gap in diagnosing and monitoring patients with stroke, traumatic brain injury (TBI) or other brain injury. Most patients are monitored with CT or MRI, which only provide snapshots. Intracranial pressure (ICP) monitors and other existing types of monitors are invasive and are therefore only used in the most serious cases. So, most brain injury patients receive no direct monitoring of their brain fluids, and only receive periodic neurological exams, which can detect problems only once they become severe enough to cause a clinically detectible neurologic deficit. At that point the situation becomes urgent, aggressive emergency intervention may be required, and irreversible damage may have already occurred.
There is a significant, critical unmet clinical need for a simple, non-invasive, continuous monitoring system for detecting small changes in brain fluids, enabling earlier intervention. Cerebrotech has the answer
Mr. Levinson is a start-up medical device executive with over 30 years of experience developing and bringing revolutionary new products to market. Mr. Levinson started Cerebrotech Medical Systems in 2011 based on a technology developed at UC Berkeley. Mr. Levinson was the start-up President and CEO for Zeltiq Aesthetics (ZLTQ), and led the development of the groundbreaking cooling technology for non-invasive fat layer reduction. Prior to Zeltiq, Mr. Levinson was the start-up VP of R&D at Thermage, which utilizes radiofrequency energy to provide non-invasive skin tightening. Thermage held its IPO in 2006, and is now part of Valeant Pharmaceuticals. Mr. Levinson was also VP of R&D at BioSurgical Corporation, developer of a novel applicator for fibrin sealant, acquired in 2000 by Baxter International. Mr. Levinson has led the development of breakthrough products at Nellcor (patient monitoring), Baxter (in vitro diagnostics), ALCOA Intercon-X, and Hewlett Packard. Many of Mr. Levinson's innovations are represented in his 37 issued U.S. patents with more pending. He earned his B.S. in Engineering Sciences from University of California at San Diego and also holds a MS in Computer Systems from University of Phoenix.
Dr. Laden co-founded TriStar Technology Ventures in 2009. Through his role at TriStar, he serves on the Board of Directors for Cerebrotech, NuSirt, Molecular Sensing and Diagnovus, and oversees TriStar’s interest in BioStable, TVA and GenomOncology. Prior to the founding of TriStar, Dr. Laden served as the Assistant Director in the Office of Technology Transfer and Enterprise Development at Vanderbilt University. Dr. Laden holds a doctorate in Toxicology from the University of Kentucky, a master’s degree in Environmental and Industrial Health from the University of Michigan and an undergraduate degree in biology from Penn State University.
Issie N. Rabinovitch is a partner at Cheyenne Capital, a venture capital firm, and sits on multiple boards of directors for his portfolio companies. Mr. Rabinovitch was the Chief Executive Officer of Mainsail Networks, a telecommunications company. He served as President and CEO of Micro Power Systems, Inc., a semiconductor products company. Mr. Rabinovitch was President of Berkeley International Capital Corporation, a venture capital firm, was President of Crowntek Software International, a software development and distribution company, and was at Xerox in various management roles. Mr. Rabinovitch holds a B.S. from McGill University and an MBA from Harvard.
Mr. Cook co-founded Mountain Group Partners in 2002. In addition to Cerebrotech, Mr. Cook currently serves on or has visitation rights to the board of directors of: Castle Biosciences,Lineagen, and MiNDERA. Mr. Cook previously served on or had visitation rights to the board of directors of: ABT Molecular Imaging, Clearside Biomedical (NASDAQ “CLSD”), Pathfinder Therapeutics, VenX, Diagnovus, and OnFocus Healthcare. Prior to his involvement with MGP, Mr. Cook was a Director, Private Placements in the Investment Banking Group of Robert W. Baird & Co., and was Vice President in the Investment Banking Group at J.C. Bradford & Co. Mr. Cook graduated with a B.A. in Economics from Davidson College.
Mr. Dieck has co-founded and held senior management positions in four neuro-interventional companies, all of which were acquired by Medtronic, Covidien or Stryker. Currently Mr. Dieck is Chairman of Synchron, Inc. a neuro-interventional company developing a minimally invasive brain machine interface. Mr. Dieck was co-founder, Chairman and CEO of Lazarus Effect, which developed a next-generation stroke treatment device and was sold to Medtronic in 2015. He previously served as CEO and board member at Nfocus Neuromedical, and Concentric Medical. As a venture investor, Mr. Dieck was an Executive Director at DFJ-ePlanet and ePlanet Capital where he had direct responsibility for the med-tech portfolio. This portfolio included BodyMedia (sold to Aliphcom / Jawbone), Spinal Modulation (sold to St Jude Medical), Zonare (sold to Mindray), DirectFlow and Intrapace. Mr. Dieck is an inventor with over 30 issued and pending patents. He received his BA in Biological Sciences from Willamette University and MBA from the University of California at Berkeley.
“We are delighted to welcome yet another extraordinary clinician, researcher and patient care advocate to the ranks of our scientific advisors.” Read Article
“Dr. Selden brings a wealth of neurosurgical expertise and academic distinction to the already notable ranks of our clinical and scientific advisors.” Read Article
Approval to market Cerebrotech's Intracranial Fluids (ICF™) Monitor in Europe paves the way for early commercial activity and European clinical studies. Read Article
Mitch Levinson will be speaking to entrepreneurs, investors and regulators at ComplianceOnline conference in San Diego on September 17, 2015. Read Article
Cerebrotech’s Intracranial Fluids Monitor is a key element of this study, as the company collaborates with world-class researchers from academia, NASA (thru NSBRI) and the German Aerospace Center (DLR). Read Article
Baylor Innovations highlights VIPS technology as a “game-changer”, according to Baylor University Medical Center department chair, Dr. Michael Foreman. Read Article
Cerebrotech was chosen by investors and industry experts as a “top-10” at this prestigious medical innovation event. Read Article
NSBRI sees Cerebrotech as part of the medical kit that accompanies astronauts on space missions. Read Article
Cerebrotech CEO interviewed after receiving grant from National Space Biomedical Research Institute (NSBRI). Read Article
Cerebrotech inventor and co-founder, Boris Rubinsky, expects his technology will be useful in detecting concussion. Read Article
University of California researchers describe results from Mexico study on TBI patients. Read Article
UC Berkeley researchers discuss new brain monitoring technology. Read Article
Cerebrotech is selected from dozens of applicants as the recipient of the 2013 SmartCAP grant from the National Space Biomedical Research Institute in Houston. Read Article
Nashville healthcare venture firm TriStar Technology Ventures makes significant investment in start-up Cerebrotech Medical Systems. Read Article
Cerebrotech Co-Founder and CEO talks about his career and his vision for Cerebrotech. Read Article